sábado, 10 de febrero de 2018

Impact of BRCA Mutation Status on Survival of Women With Triple-negative Breast Cancer. - PubMed - NCBI

2017 Dec 30. pii: S1526-8209(17)30334-8. doi: 10.1016/j.clbc.2017.12.014. [Epub ahead of print]

Impact of BRCA Mutation Status on Survival of Women With Triple-negative Breast Cancer.

Yadav S1, Ladkany R2, Yadav D3, Alhalabi O4, Khaddam S5, Isaac D6, Cardenas PY7, Zakalik D8.

Author information

Abstract

INTRODUCTION:

The effect of germline BRCA mutations on the outcomes of patients with triple-negative breast cancer (TNBC) is not well understood.

MATERIALS AND METHODS:

The present retrospective study included women with newly diagnosed TNBC from January 1, 2004 to December 30, 2013. The demographic and tumor characteristics, genetic testing results, and outcomes were collected by a review of the patients' medical records. The outcomes were compared between the BRCA+ and BRCA- women. Kaplan-Meier curves were plotted for survival analysis, and Cox proportional hazard regression was used to determine the predictors of recurrence-free survival.

RESULTS:

A total of 266 TNBC patients who had undergone BRCA testing were included in the final analysis. Of the 266 patients, 72 (27.0%) tested positive for a pathogenic BRCA mutation and 194 (73.0%) tested negative. BRCA+ women were more likely to be diagnosed with breast cancer at a younger age than were the BRCA- women. Mutation carriers were also more likely to undergo bilateral mastectomy and less likely to receive radiation. The 2- and 5-year overall survival in BRCA+ women was 97.1% and 83.1% and was 97.3% and 89.7% in the BRCA- women, respectively. No statistically significant difference was found in overall survival between the BRCA+ and BRCA- group. No statistically significant difference was noted in the rate of locoregional recurrence, distant recurrence, or recurrence-free survival between the BRCA+ and BRCA- women.